DuraGraft improves clinical outcomes by reducing the incidence and complications of graft failure

Read More

ABOUT SOMAHLUTION

Somahlution is an innovation-driven global company specializing in the development and marketing of products that make a meaningful difference in healthcare.

Experienced Team

Somahlution has assembled a team of experienced executives, employees, advisors and consultants to advance its mission

Competitive Advantages

Somahlutions flagship product, DuraGraft, is first in class. DuraGraft has been designed for strong, superior performance as compared to other standard of care products. The superior design has long lasting health benefits to patients, and supportive health economic benefits to hospitals

Market Expansion

Somahlution is expanding its markets through strategic collaborations with key partners

A Leading

Innovator in the Global Biotechnology Market

Somahlution is dedicated to developing, manufacturing, and marketing products of the highest quality to serve the needs of our customers worldwide. Our scientific and medical expertise, with a unique patient-inspired focus, forms the foundation of our commitment to science with a purpose.

Who We Are?

Somahlution is a privately-held global biotechnology company headquartered in Jupiter.

Somahlution Quality

Somahlution is dedicated to developing, manufacturing, and marketing products of the highest quality to serve the needs of our customers worldwide.

Somahlution Culture

A global leader in the discovery, development and commercialization of innovative, high value-added solutions to advance clinical performance..

OUR PRODUCTS

DuraGraft is a vascular graft treatment that improves clinical outcomes by reducing the incidence and complications of graft failure. DuraGraft enhances CABG outcomes by significantly reducing major cardiac events such as repeat revascularization, myocardial infarction and MACE.

0
0
Reduction in Myocardial Infarction Rates
0
0
Reduction in Repeat Revascularization Rates
0
0
Reduction in MACE Rates

Medical & Hospital Professionals

At Somahlution, we work with medical professionals and hospitals to provide new medical technologies that not only benefit patients globally, but also help hospitals improve their quality performance ratings.

Read More

LATEST NEWS

blog_image

NICE Publishes a Medtech Innovation Briefing (MIB) on DuraGraft® for Preserving Vascular Grafts and Associated Endothelium used in Coronary Artery Bypass Graft (CABG) Surgery.

on 05 Jun, 2019

Read More
blog_image

Somahlution Announces Study Results Showing DuraGraft® Vascular Graft Treatment Improves Long-Term Outcomes in Coronary Artery Bypass Grafting Surgery

on 07 Apr, 2017

Somahlution Announces Study Results Showing DuraGraft® Vascular Graft Treatment Improves Long-Term Outcomes in Coronary Artery Bypass Grafting Surgery First-in-class intraoperative vascular graft treatment shown to reduce the risk of graft failure. Results...

Read More
blog_image

Somahlution announced enrollment of the first subject in their DuraGraft® CABG European Registry

on 28 Feb, 2017

JUPITER, Fla., Jan. 4, 2017 — Somahlution, a global biotechnology company developing products to reduce the burden of ischemia reperfusion injury in tissue grafting, organ transplant and other surgical indications, today announced enrollment...

Read More